Analysis of minimal residual disease (MRD) in childhood acute myeloid leukemia (AML) may predict for clinical outcome. MRD levels were assessed by flowcytometric immunophenotyping in 94 children with AML enrolled into a single trial (United Kingdom Medical Research Council AML12 and similar Dutch Childhood Oncology Group ANLL97). An aberrant immunophenotype could be detected in 94% of patients. MRD levels after the first course of chemotherapy predicted for clinical outcome: 3-year relapse-free survival was 85% ± 8% (s.e.) for MRD-negative patients (MRDo0.1%), 64%±10% for MRDlow-positive patients (0.1%pMRDo0.5%) and only 14±9% for MRD-high-positive patients (MRDX0.5%; Po0.001), whereas overall survival was 95% ± 5%, 70% ± 10% and 40% ± 13%, respectively, (Po0.001). Multivariate analysis allowing for age, karyotype, FLT3-internal tandem duplications and white blood cell count at diagnosis showed that MRD after the first course of chemotherapy was an independent prognostic factor. Although comparison of paired diagnosis-relapse samples (n ¼ 23) showed immunophenotypic shifts in 91% of cases, this did not hamper MRD analysis. In conclusion, flowcytometric MRD detection is possible in children with AML. The level of MRD after the first course of chemotherapy provides prognostic information that may be used to guide therapy.
Introduction
The outcome for children with acute myeloid leukemia (AML) has improved considerably over the past three decades. This improvement has arisen from a combination of intensified chemotherapy and developments in supportive care, including antifungal prophylaxis/treatment, blood product support, and greater access to intensive care facilities when required. Despite these improvements, 30-40% of patients relapse, indicating that current chemotherapy regimens do not consistently eradicate all malignant cells. Furthermore, the improvement in outcome is achieved at the expense of delivering very intensive chemotherapy to all children with resultant acute treatment-related toxicity and late morbidity. Stem cell transplantation is usually restricted to poor risk patients to limit transplant related morbidity and mortality to those patients at greatest risk of relapse. It is important to identify both patients who need intensive treatment, including stem cell transplantation to prevent relapse, and patients who can be cured with the current (or potentially even less intensive) protocols, if treatment is to be tailored to need and treatment-related morbity and mortality is be limited.
Several studies have shown that detection of minimal residual disease (MRD) in AML is an independent prognostic factor. [1] [2] [3] [4] [5] [6] [7] [8] [9] Most MRD studies in AML have focused on adults, and relatively little is known about the prognostic significance of MRD in childhood AML. Sievers et al. 3 showed, in a retrospective flowcytometric MRD study, that the relative risk of relapse in MRD-positive pediatric AML patients was 2.8 times the risk of relapses in MRD-negative patients. MRD was monitored using a standard three-color immunophenotyping protocol and occult leukemia was defined as more than or equal to 0.5% blasts with aberrant surface antigen expression. In a more recent study from the same group, using a comparable flowcytometric approach and the same cut-off level of 0.5%, patients with occult leukemia after induction therapy were almost five times more likely to relapse than those lacking detectable MRD. 4 A flowcytometric study by Coustan-Smith et al. 1 reported pediatric AML patients with MRD levels 40.1% after induction therapy to have a 2-year survival estimated at 33%, compared with 72% for MRD-negative patients. This four-color flowcytometric study detected a leukemia-associated immunophenotype (LAIP) in 85% of patients with sensitivities of 0.1-0.01% using patienttailored labelings. In the recent MRD-AML-BFM Group study (the first European flowcytometric MRD study in childhood AML), 2 a standard four-color flowcytometric analysis was used with cut-off values dependent on the time point and specificity of the LAIP. MRD positivity before second induction was associated with a more than twofold risk of relapse, although MRD levels were not a significant factor in multivariate analysis. 2 These data indicate that MRD may be of clinical significance in children with AML, but that optimal time points (TPs) and cutoff levels are dependent on the flowcytometric methodology and on the treatment protocol. In this study, we evaluated the clinical significance of MRD in pediatric AML patients enrolled into the identical United Kingdom Medical Research Council (MRC) AML12 and Dutch Childhood Oncology Group (DCOG) ANLL97 protocols.
Materials and methods

Patients
Between April 2001 and December 2004, DCOG ANLL97 (similar to UK MRC AML12) was the national protocol for children with AML in The Netherlands and 93 patients were registered. Patients treated on DCOG ANLL97 were eligible for this MRD study. In all, 16 patients were excluded because of the extramedullary myeloid tumor without bone marrow (BM) involvement (n ¼ 4), treatment on an alternative protocol (n ¼ 9), no diagnostic BM sample available (n ¼ 2), or no informed consent for MRD analysis (n ¼ 1). In addition, five patients with acute promyelocytic leukemia (PML-RARA positive) were excluded. The remaining 72 AML patients are included in this report.
Between October 2000 and May 2002, 27 children with AML diagnosed in Glasgow, Sheffield, Bristol, Edinburgh, Leeds, Liverpool and Dublin and treated on the UK MRC AML12 protocol were recruited to this MRD study. Three patients were excluded because no diagnostic BM sample was available. An additional two patients with acute promyelocytic leukemia (PML-RARA positive) were also excluded. The remaining 22 patients are reported in this study.
In total, 94 children with AML form the participants of this report with a median follow-up time of 49 months. The MRC patients did not differ from the DCOG patients with respect to gender, age, French-American-British (FAB) classification, diagnostic white blood cell count, presence of fusion genes (AML1-ETO, CBFB-MYH11), presence of FLT3-internal tandem duplications (ITDs) or relapse rate (Table 1) . The institutional review board of each participating center approved this study and informed consent for study participation was obtained from each patient or legal guardian.
MRC AML12/DCOG ANLL97 protocol
The MRC AML12/DCOG ANLL97 protocol ( Figure 1 ) consisted of two induction courses (Ara-C, daunorubicin, etoposide or mitoxantrone, Ara-C, etoposide, determined by randomization) followed by a third course (amsacrin, Ara-C, etoposide). Patients were stratified according to cytogenetics and response after course 1. 10 The good risk-group included all patients positive for inv (16) or t(8;21). The poor-risk group included patients with 420% blasts in BM after the first course of chemotherapy as determined by morphology and patients with specific unfavorable karyotypes. All other patients were in the standard-risk group. All patients in the first remission were eligible for a second randomization between four (MidAC) versus five courses (MidAC and CLASP) of chemotherapy. If a matched sibling donor was available for standard-risk or high-risk patients, the last course of chemotherapy (fourth or fifth) was replaced by allogeneic stem cell transplantation.
Cell samples
BM samples were obtained at diagnosis (TP1; n ¼ 94), after the first course of chemotherapy (TP2; n ¼ 58), after the second course of chemotherapy (TP3; n ¼ 29), after the third course of chemotherapy (TP4; n ¼ 28) and at the end of treatment (TP5; n ¼ 30). Follow-up samples were obtained after hematological recovery. In a subset of United Kingdom patients, paired BM and peripheral blood (PB) samples were obtained at the same TPs after diagnosis. All 94 patients were evaluated for the presence of LAIPs at diagnosis. From 67 patients, at least one follow-up sample was available (median: two samples per patient) and these patients were included in the MRD part of this study. These 67 patients did not differ significantly from the total group of 94 patients.
Samples from Dutch patients, excluding those patients diagnosed in Erasmus MC-Sophia, were sent to the laboratory of the DCOG by overnight transport. Samples from patients diagnosed in Erasmus MC-Sophia were transported directly to Erasmus MC, Department of Immunology. Samples from United Kingdom patients were sent by express courier to Erasmus MC, Department of Immunology. On arrival, samples were analyzed immediately for flowcytometric immunophenotyping; remaining cells were subjected to Ficoll density centrifugation and RNA was isolated from the mononuclear cells. RNA was stored for PCR analysis, which was carried out by the Department of Immunology, Erasmus MC. All samples were processed within 36 h of sampling and generally within 24 h.
Immunophenotyping at diagnosis
At diagnosis, BM and/or PB samples were incubated with ammoniumchloride to lyse erythrocytes and the leukocytes obtained were used for flowcytometry. All samples were screened using four-color labelings to confirm the presence of AML. 11 In a second step, the applied protocol focused on the 
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Clinical significance of MRD in pediatric AML VHJ van der Velden et al detection of aberrant immunophenotypes (see Supplementary  Table 1 ). This protocol was fully standardized between the department of Immunology, Erasmus MC and the DCOG. CD45 was included in each labeling to facilitate uniform gate settings and subsequent analysis (using Cell Quest Pro, BD Biosciences, San Jose, CA, USA). On the basis of the diagnostic results, one or more patienttailored quadruple labelings were designed to measure MRD in follow-up BM and/or PB. Although we aimed for LAIPs expressed on all leukemic cells, in practice the percentage of leukemic cells expressing the LAIP varied from 6 to 100% (median: 80%). To determine the potential sensitivity of the 65 LAIPs, the same labelings were carried out on three BM samples obtained from healthy individuals or patients without a hematological malignancy (referred to as 'normal BM').
Detection of fusion gene transcripts and FLT3-ITD at diagnosis
At diagnosis, fusion gene transcripts were detected as previously described.
12,13 FLT3-ITD were detected at the RNA level using the 11F and 12R primers as described, 14 followed by agarose gel electrophoreses and sequencing of abnormally sized PCR products. As shown in Table 1 , AML1-ETO and CBFB-MYH11 fusion gene transcripts were detected in 16 and 5% of patients, respectively, and FLT3-ITD in 19% of patients, including one patient with AML1-ETO.
Immunophenotyping during follow-up
Follow-up BM and/or PB samples were incubated with ammonium chloride to lyse erythrocytes and the leukocytes obtained were used for flowcytometry. This approach was chosen because bulk-lysis before the staining results in fully identical cell suspensions in the separate tubes (thereby facilitating comparison between tubes) and allows the use of a fixed cell concentration for the stainings.
Four standardized labelings (see Supplementary Table 1 , first phase) were carried out on follow-up samples to establish the overall composition of the sample, followed by patient-tailored labeling(s) for MRD detection. Preferably one million events were acquired per patient-tailored labeling in order to reach theoretical sensitivities of p0.01% (that is, 100 events for clear recognition of a population); this was possible in over 80% of samples. In all samples at least 100 000 cells could be acquired (theoretical sensitivity p0.1%). Data were analyzed using Painta-Gate Pro software (BD Biosciences). During regular meetings between the DCOG and the department of Immunology, Erasmus MC, the design and analysis of patient-tailored labelings was discussed and experience was exchanged. Using common guidelines for data analysis (particularly focused on preventing false-positive MRD results), independent analysis of electronic data files showed good agreement between both the centers (intraclass correlation coefficient: 0.71), which was comparable with the intraobserver variability (intraclass correlation coefficient: 0.90). Furthermore, MRD levels detected in BM samples obtained at the various time points did not differ significantly between the two laboratories (data not shown).
Statistical analysis
For continuous and categorical data the Mann-Whitney test or the Chi-square test/Fisher's exact test was used in the comparison of groups. Analysis of longitudinal changes in logtransformed MRD levels was carried out using repeated measurements analysis of variance. Relapse-free survival (RFS) was calculated from the date of MRD TP to the date of the last follow-up or relapse and was censored for death in complete remission. Overall survival (OS) was calculated from the date of MRD TP to death or to the date of the last follow-up. Probabilities of 3-year survival data were estimated using the Kaplan-Meier method with standard errors (s.e.) according to Greenwood and were compared with the log-rank test. Multivariate analysis was carried out using Cox regression analysis and hazard ratios (HRs) with 95% confidence interval are reported. Correlation coefficients given are Spearman's rho. A P-value of 0.05 (two-sided) was considered the limit of Clinical significance of MRD in pediatric AML VHJ van der Velden et al significance in all analyses. Statistical analyses were carried out using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA).
Results and discussion
Identification of LAIP at diagnosis
Flowcytometric immunophenotyping at diagnosis confirmed the presence of AML in all 94 patients. In 85% of patients, subpopulations of leukemic cells (X20%) could be observed for at least one antigen. To limit the risk of false negative MRD results, wherever possible two or more LAIPs were monitored per patient (68% of cases), but in 26% of patients only one LAIP could be defined and in 6% no LAIP could be defined (6 patients: one FAB-M1, one FAB-M2, two FAB-M4, and two FAB-M5). These data are comparable to those of Coustan-Smith et al. 1 and Langebrake et al., 2 who detected LAIPs in 85 and 98% of pediatric AML patients, respectively. The median percentage of leukemic cells expressing at least one LAIP was 93% (range: 32-100%).
Immunophenotypic abnormalities at diagnosis included cross-lineage antigen expression (for example, CD2, CD7, CD56) in 80% of patients, antigen over-or under-expression (e.g. CD34) in 26% of patients, and asynchronous antigen expression (for example, CD34 þ CD11b þ) in 82% of patients. This frequency of the various aberrant immunophenotypes seems to be higher than that published for adult AML, particularly the frequency of cross-lineage antigen expression (particularly CD7 and CD19). 6, 7 The presence of certain aberrant immunophenotypes was associated with genetic abnormalities. CD19 positivity was found in 69% of AML-ETO1-positive patients and only 8% in AML-ETO1-negative patients (Po0.05 by Chi-square). CD2 positivity was found in 60% of CBFB-MYH11-positive patients and only 15% in CBFB-MYH11-negative patients (Po0.05). Patients with FLT3-ITD had more often expression of CD2 (42 versus 12%; Po0.05) and CD7 (75 versus 29%; Po0.05) than patients with wild-type FLT3, whereas CD7 was less frequently expressed (0 versus 38%; Po0.05). It should, however, be noted that the number of patients with particular genetic abnormalities is relatively low and consequently the data should be interpreted with caution.
To determine the potential sensitivity of the 65 used LAIPs, these labelings were analyzed on three normal BM samples. In 38% of LAIPs a sensitivity of at least 0.01% was achieved and in 94% of cases the sensitivity was at least 0.1% (Supplementary  Table 2 ). These data are in concordance with the data by the MRD-AML-BFM Study Group, who detected highly specific immunophenotypes (o0.05%) in 33% and medium specificity (0.04-0.19%) in 71% of patients (using a fixed antibody panel for monitoring). 15 In the study by Coustan Smith et al.,
1 sensitivities of at least 0.01% were found in 57% of LAIPs. In conclusion, flowcytometric MRD analysis reaching a sensitivity of at least 0.1% (10 À3 ) is possible for the vast majority of pediatric AML patients.
MRD levels at various time points
Of the 94 patients recruited to this study, two patients (2%) died early (within 1 month of diagnosis) and 36 patients relapsed (38%). The 3-year OS was 68%, similar to the outcome of all patients treated in the MRC AML12/DCOG ANLL97 trials (data not shown). 16 In all, 9 of the 92 patients alive after the second course of chemotherapy did not achieve morphological remission and were excluded from subsequent MRD analysis; this concerned all high-risk patients. The level of MRD positivity after the first course (TP2), after the second course (TP3), after the third course (TP4) and at the end of therapy (TP5) is shown in Figure 2a . Analysis of the longitudinal changes in MRD levels showed a significant difference in the profiles of means between patients who remained in continuous complete remission for at least 3 years and those who relapsed (P ¼ 0.02) (Figure 2b ). Whereas mean MRD levels did not change significantly over time in patients in continuous complete remission, mean MRD levels in relapsed patients were significantly higher at TP2 compared with the later three TPs (P ¼ 0.003) (Figure 2b) . No significant differences were observed between the later three TPs (TP3, TP4, TP5), which might be because of the smaller sample size.
Prognostic significance of MRD in the MRC AML12/ DCOG ANLL97 protocol
Using a minimum sensitivity of 0.1% for flowcytometric MRD analysis, patients were initially classified at all TPs into MRD negative (MRD level o0.1%) and MRD positive (MRD level X0.1%). After the first course of chemotherapy (TP2), MRDnegative patients (n ¼ 20; 34% of patients) had a significantly higher 3-year RFS than MRD-positive patients (n ¼ 38; 66%): 
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VHJ van der Velden et al 85%±8% versus 44%±8% (P(log rank) ¼ 0.002; Figure 3a ) and a significant better 3-year OS of 95% ± 5% versus 58% ± 8% (P (log rank) ¼ 0.006; Figure 3b ). This MRD classification showed no prognostics significance at later TPs, which might be because of the smaller sample size. MRD-positive patients were subclassified by their MRD level after the first course of chemotherapy into MRD-low positive (MRD level between 0.1 and 0.5%) and MRD-high positive (MRD level X0.5%).
As shown in Figure 3c , the three resulting MRD-based groups significantly differed in 3-year RFS: MRD-negative patients (n ¼ 20; 34%), MRD-low-positive patients (n ¼ 23; 40%), and MRD-high-positive patients (n ¼ 15; 26%) had a 3-year relapse free survival of 85%±8%, 64%±10, and 14%±9, respectively, (Po0.001). Of note, half of all relapses occurred in the relatively small group of MRD-high-positive patients. MRD-based risk group classification at TP2 also correlated significantly with the OS (Po0.001; Figure 3d ). No significant differences between MRD-negative and MRD-positive patients (cut-off: 0.1%) beyond TP2 and outcome were found. (TP3: 73%±13% versus 62% ± 14%, P ¼ 0.37; TP4: 62% ± 14% versus 50% ± 14%, P ¼ 0.36; TP5: 67% ± 11% versus 79% ± 14%, P ¼ 0.47). However, at TP3 MRD-high-positive patients (MRD level X0.5%) showed a significantly worse RFS and OS as compared with MRD-negative/low-positive patients (RFS: 17% ± 15% versus 80% ± 9%, P ¼ 0.001; OS: 20% ± 18% versus 79% ± 9%, P ¼ 0.002). At TP4 and TP5 RFS and OS did not differ between both groups (data not shown). MRD after the first course of chemotherapy (TP2) retained its prognostic significance even when good risk patients (AML1-ETO or CBFB-MYH11 fusion gene transcript positive) were excluded: 3-year RFS for MRD-high-positive, MRD-lowpositive, and MRD-negative patients was 83%±11%, 59% ± 12%, and 17% ± 11%, respectively, (P (log rank)o0.001), whereas 3-year OS was 83%±11%, 61%±12%, and 39%±14, respectively (P (log rank) ¼ 0.004). Of eight patients with AML1-ETO fusion gene transcripts and MRD data available at TP2, four were MRD negative, three MRD-low positive and one MRD-high positive. One MRD-high-positive patient and one MRD-low-positive patient relapsed, whereas all MRD-negative patients remained in complete remission. The number of patients with CBFB-MYH11 fusion gene transcripts and MRD data at TP2 was too small for meaningful analysis.
These results are in agreement with previous reports on the prognostic significance of MRD in pediatric AML patients, including the recent studies by the MRD-AML-BFM Study Group 2 and St Jude, 1 which indicate that MRD levels after the first induction course are significantly related to outcome. In the large Children's Cancer Group study of 252 children and adolescents with AML, additional prognostic significance was found for MRD levels at the end of consolidation. 4 This is in agreement with a number of MRD studies in adult AML patients, which showed that MRD levels after both induction and consolidation correlate with RFS, [5] [6] [7] 17 although some studies found only MRD levels after consolidation to be significant. 8, 9, 18 Whereas MRD data obtained after consolidation therapy may have limited clinical usefulness for risk adapted therapy-tailoring, MRD data obtained after induction therapy allows treatment to be tailored to a patient's risk of relapse. This might avoid exposure to Clinical significance of MRD in pediatric AML VHJ van der Velden et al the unnecessary therapy in MRD-low patients, whereas MRD-high patients might benefit from intensified therapies.
MRD is an independent prognostic factor
Using the univariate Cox regression model for RFS risk assessment, MRD at TP2 (X0.5% versus o0.5%) was shown to be statistically significant with a HR for relapse of 6.8 (95% confidence interval: 3.0-15.4; Po0.001) and a HR for OS of 4.8 (95% confidence interval: 1.9-11.8). In the same group of 58 patients, the HR for relapse of the karyotypic subgroups (good-risk: AML1-ETO or CBFB-MYH11 positive; standard-risk: all other patients) 10 was 3.1 (95% confidence interval: 0.7-13.2), but this didn't reach statistically significance in our relatively small series (P ¼ 0.127). In all, 19 out of 48 standard-risk patients died, whereas all 10 good-risk patients survived (P(log rank) ¼ 0.02). These data suggest that MRD at TP2 is a better predictor of RFS than the conventional risk group stratification. Also the presence of FLT3-ITD was significantly associated with RFS in the univariate analysis (P ¼ 0.03), whereas age had no prognostic impact (Table 2) .
To evaluate the independent prognostic significance of MRD, multivariate analysis allowing for age, karyotype, the presence or absence of FLT3-ITD and MRD-based risk group classification after the first course of chemotherapy (TP2) was carried out. Because of the relatively small numbers, patients were classified as MRD-high positive (MRDX0.5%) or MRD-negative/low positive (MRDo0.5%). MRD at TP2 was an independent prognostic factor for RFS and for OS ( Table 2) . Also MRD at TP3 was an independent prognostic factor for RFS and OS (HR 14.9 (2.2-104), P ¼ 0.006; OS: HR 14.8 (2.8-79), P ¼ 0.002). These findings are in agreement with most other published MRD studies in AML, which also reported MRD to be of independent prognostic significance for relapse-free and OS. In the recent MRD-AML-BFM Study Group, however, MRD did not increase the prognostic power of the well defined BFM risk factors (FAB subtype, cytogenetics and morphologically determined blasts at day 15).
2 Day 15 blast data were not available for the patients of this cohort and therefore, the additional discriminatory value of MRD to the day 15 blast count could not be established in this study.
Stability of LAIP between diagnosis and relapse
To investigate whether immunophenotypic shifts occurred between diagnosis and relapse, we compared the immunophenotypes of 27 of 41 relapsed patients for whom paired diagnostic and relapse samples were available. Immunophenotypic shifts at relapse were observed in 21 out of 27 paired diagnosis and relapse samples (78%). Comparable data have been reported in adult AML patients (90%) 19 and in a recent pediatric AML study (88%). 20 Furthermore, in common with the study by Langebrake et al., 20 we observed that the immature markers CD34, CD117 and HLA-DR were more frequently gained, whereas the differentiation markers CD14, CD11b and CD15 were more frequently lost at relapse, suggesting that the immunophenotype of the leukemic population at relapse was more immature.
Most importantly, MRD detection was possible using the patient-tailored labeling(s) in 23 out of the 27 (85%) relapsed patients. Voskova et al. 21 found at least one stable LAIP in 76% of adult patients with AML. In this study, in only four patients the applied LAIP labelings did not detect the majority of leukemic cells at relapse. However, all four patients were classified as For the multivariate analysis, only patients with a conventional standard risk-group (n ¼ 48) were included in the overall survival analysis due to the absence of deaths in the 10 good-risk patients. Data present P-values and HR with their 95% CI. c Good-risk patients are positive for CBFB-MYH11 or AML1-ETO fusion gene transcripts, whereas standard risk patients are negative. Both patients groups have less than 20% of blasts in their bone marrow after the first course of chemotherapy. As none of the high-risk patients achieved complete remission after the second course of chemotherapy, these patients were excluded from the analysis. Clinical significance of MRD in pediatric AML VHJ van der Velden et al MRD-high positive at TP2, indicating that the immunophenotypic shift at relapse did not hamper reliable MRD detection at this early TP.
MRD in paired BM and PB samples
Obtaining PB samples from children (usually under general anesthetics) is less traumatic than BM samples and therefore, we evaluated whether PB samples could replace BM samples for MRD analysis by analyzing 43 paired BM-PB samples obtained from 18 patients. Furthermore, MRD analysis in PB samples may be simpler because of the virtual absence of myeloid progenitor cells in PB. Higher MRD levels in BM were associated with higher levels in PB (r ¼ 0.85), but MRD levels in PB were consistently lower than in BM samples (Figure 4 ). Most importantly, the ratio between the MRD level in the BM sample and the corresponding MRD level in the PB sample was variable, ranging from 1 to more than 100-fold. This implies there is no straightforward relationship between MRD levels in paired PB and BM samples and that PB samples cannot easily replace BM samples for MRD monitoring. The higher MRD levels in BM are in keeping with the BM origin of AML, comparable with our earlier findings in ALL. 22 Similar findings have been reported for MRD analysis in adult CBFB-MYH11-positive AML patients. 23 In contrast, two adult MRD studies reported comparable MRD levels between BM and PB. 24, 25 The reasons for these discrepancies are not clear, but technical variance seems unlikely and differences in biology of the leukemic cells may be an explanation.
Although MRD levels in PB do not reflect MRD levels in BM, MRD information from PB samples still may have prognostic significance.
13,24-26 However, we found no prognostic significance for PB MRD at TP2 with no difference in levels between patients who remained in remission and those who relapsed (data not shown).
Conclusions
In conclusion, flowcytometric MRD detection is feasible in the vast majority of pediatric AML patients. The MRD level obtained after the first course of induction chemotherapy is a significant and independent prognostic factor for RFS. Larger prospective studies are needed to determine the prognostic significance of MRD at later time points during and after therapy. MRD measurement may be particularly useful in identifying patients at high risk of relapse, who may benefit from treatment intensification with novel therapies, 27 although this requires to be shown by randomized trials. Finally, flowcytometric MRD monitoring in childhood AML may be improved by focusing on leukemic stem cells and by the introduction of eight-color flowcytometers with new software programs for automated data analysis.
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